A multi-centre, randomized, double blind, parallel group study to investigate efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.
Latest Information Update: 02 Dec 2016
Price :
$35 *
At a glance
- Drugs ONO 5334 (Primary) ; Alendronic acid
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Acronyms OCEAN
- 05 Dec 2012 Planned number of patients changed from 265 to 285 as reported by European Clinical Trials Database record.
- 24 Mar 2012 Quantitative computed tomography results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
- 20 Sep 2011 Results assessing changes in levels of bone turnover markers presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.